Phibro Animal Health (NASDAQ:PAHC) Stock Rating Lowered by Zacks Research

Phibro Animal Health (NASDAQ:PAHC) was downgraded by equities researchers at Zacks Research from a “strong-buy” rating to a “hold” rating in a report released on Tuesday, Zacks reports.

Separately, Weiss Ratings upgraded shares of Phibro Animal Health from a “hold (c+)” rating to a “buy (b-)” rating in a report on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $46.50.

Phibro Animal Health Trading Up 1.5%

Shares of PAHC opened at $35.15 on Tuesday. The stock’s fifty day simple moving average is $36.89 and its 200-day simple moving average is $40.93. The firm has a market capitalization of $1.43 billion, a PE ratio of 14.00 and a beta of 0.42. Phibro Animal Health has a 12-month low of $28.25 and a 12-month high of $60.08. The company has a quick ratio of 1.28, a current ratio of 3.20 and a debt-to-equity ratio of 1.70.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, November 4th. The company reported $0.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.01. Phibro Animal Health had a return on equity of 35.88% and a net margin of 6.66%. The firm had revenue of $386.77 million during the quarter, compared to analysts’ expectations of $382.42 million. As a group, research analysts predict that Phibro Animal Health will post 3.48 earnings per share for the current year.

Hedge Funds Weigh In On Phibro Animal Health

Institutional investors have recently bought and sold shares of the company. Advisors Asset Management Inc. acquired a new position in shares of Phibro Animal Health in the 3rd quarter valued at $20,546,000. Boston Partners bought a new position in Phibro Animal Health during the 3rd quarter valued at $10,907,000. Ranger Investment Management L.P. bought a new stake in shares of Phibro Animal Health in the 2nd quarter worth about $9,182,000. Globeflex Capital L P bought a new stake in shares of Phibro Animal Health in the 2nd quarter worth about $5,942,000. Finally, Allspring Global Investments Holdings LLC raised its stake in shares of Phibro Animal Health by 145.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company’s stock valued at $15,671,000 after purchasing an additional 169,628 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation develops and markets products for animal health and nutrition. Its portfolio includes vaccines, medicated feed additives, and nutritional specialty products designed to support the health and productivity of livestock and other animals. The company also supplies trace minerals and related products used in animal nutrition and other applications. Its products serve markets including poultry, cattle, swine, and aquaculture, and are sold to customers in the United States and internationally.